Osinga, T. E.
Oosting, S. F.
van der Meer, P.
de Boer, R. A.
Kuenen, B. C.
Rutgers, A.
Bergmann, L.
Oude Munnink, T. H.
Jalving, M.
van Kruchten, M.
Article History
Accepted: 15 November 2021
First Online: 21 January 2022
Conflict of interest
: The University Medical Centre Groningen has received research grants and/or fees from AstraZeneca, Abbott, Bristol Myers Squibb (BMS), Novartis, Novo Nordisk and Roche. S. F. Oosting has received a research grant, which was paid to the institution, from Celldex and Novartis. R. A de Boer has received speaker fees from Abbott, AstraZeneca, Novartis and Roche. L. Bergmann has received a financial grant for a non-clear cell renal cell carcinoma clinical trial from BMS. M. Jalving has received advisory board honoraria, which were paid to the institution, from Merck, BMS, Novartis, Pierre Fabre, Tesaro and AstraZeneca, speaker’s fees from Sanofi and support for clinical studies from BMS, AbbVie, Merck and Cristal Therapeutics. T. E. Osinga, P. van der Meer, B. Kuenen, A. Rutgers, T. H. Oude Munnink and M. van Kruchten declare that they have no competing interests.